|Description||Olcegepant, also called as BIBN4096BS or BIBN 4096, is the first potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor(IC50= 0.03 nM) and has been shown to block all effects of infused CGRP (2) and should ef|
|Synonyms||N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide Olcegepant Olcegepant [INN] BIBN-4096BS BIBN 4096 BS CHEMBL2071|
|Solubility||Soluble to ≥ 50 mg/mL in DMSO|
|Storage||Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -52℃ for long term (months to years).|
|Shelf Life||2 years|
|Boiling Point||1091.9±65.0 °C | Condition: Press: 760 Torr|
Ubrogepant is and selective oral calcitonin gene-related peptide (CGRP) receptor antagonist originated by Merck & Co. In Sep 2016, Allergan initiated a phase II...
Olcegepant, also called as BIBN4096BS or BIBN 4096, is the first potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) re...
MK-3207 is a potent CGRP receptor antagonist with IC50 and Ki of 0.12 nM and 0.022 nM, highly selective versus human AM1, AM2, CTR, and AMY3.
Telcagepant is a calcitonin gene-related peptide(CGRP) receptor antagonist under development for the acute treatment and prevention of migraine. It is a highly ...
Olcegepant hydrochloride is the first potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor with 150-fold select...
BMS694153 is a potent and selective calcitonin gene-related peptide(CGRP) receptor antagonist. It is related with the pathogenesis of migraine.
Rimegepant, a CGRP receptor antagonist, has been found to have potential effect against Migraine by Bristol-Myers Squibb. The Phase II trial of it has already b...
MK-3207 is a orally active and potent calcitonin gene-related peptide (CGRP) receptor antagonist IC50 vaule of 0.12 nM and Ki value of 0.024 nM. It is highly se...